ICCC
IMMUCELL CORP /DE/
NASDAQ · Healthcare · Biotechnology · US
$10.51
−2.23%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- $0.05
- Revenue estimate
- $5.4M
Latest reported
- Last report date
- Aug 14, 2026
- EPS actual
- $0.20
- EPS estimate
- $0.05
- Revenue actual
- $7.2M
- Revenue estimate
- $5.4M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 0
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +310.0%
- Revenue beats (12Q)
- 3
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 14, 2026 | $0.05 | $0.20 | Beat 300.00% | $7.2M |
| May 15, 2026 | $0.05 | $0.21 | Beat 320.00% | $10.4M |
| Mar 4, 2026 | — | -$0.31 | — | $7.6M |
| Nov 13, 2025 | — | -$0.02 | — | $5.5M |
| Aug 14, 2025 | — | $0.06 | — | $6.4M |
| May 14, 2025 | — | $0.16 | — | $8.1M |
| Nov 13, 2024 | — | -$0.09 | — | $6.0M |
| Feb 27, 2024 | — | -$0.15 | — | $5.1M |
| Nov 13, 2023 | — | -$0.12 | — | $5.4M |
| Aug 10, 2023 | — | -$0.18 | — | $3.5M |
| May 11, 2023 | — | -$0.30 | — | $3.4M |
| Feb 21, 2023 | — | -$0.22 | — | $3.9M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026